5 October 2023 in EP Europace
TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802). TauroPace is safe but more effective than H2O2 in reducing CIED infection. ClinicalTrials.gov Identifier: NCT05576194
1 May 2000 in Pacing and Clinical Electrophysiology
12 November 2025 in Advanced Healthcare Materials
Implantable medical devices, including cardiac electronic implants, joint prostheses, and breast implants, are essential to modern healthcare but remain susceptible to infection from microbial contamination during placement. Staphylococcus spp . and Candida albicans are the predominant pathogens, often causing severe complications, increased mortality, and substantial healthcare costs. With antibiotic resistance on the rise, intraoperative surface disinfection has emerged as a critical yet underutilized preventive strategy. Taurolidine, a broad‐spectrum antimicrobial with a strong safety profile and no known resistance, can be applied directly to both tissues and device surfaces. To replicate intraoperative decontamination, taurolidine‐saturated swabs are tested under standardized mechanical wiping using the European Norm EN 16615 “4‐field test.” The model reproduced short contact times and organic load conditions reflective of clinical practice, enabling assessment of both chemical and mechanical antimicrobial effects. Taurolidine achieved >5 log 10 reductions in Staphylococcus aureus , Pseudomonas aeruginosa , and Candida albicans , and >4 log 10 for Enterococcus hirae . The observed activity demonstrated a surface‐driven, enzyme‐independent mechanism involving spontaneous release of reactive N‐methylol functional groups that disrupt microbial membranes. Taurolidine's enzyme‐independent antimicrobial mechanism distinguishes it from solvent‐ or oxidant‐based disinfectants. These results support taurolidine as a potential adjunctive prophylactic agent to reduce device‐related infections during implantation procedures.
1 May 2006 in Heart Rhythm